From WikiProjectMed
Jump to navigation Jump to search
Clinical data
Trade namesEbernet
Legal status
Legal status
  • US: Not FDA approved
  • 1-(1,3-Dichloro-6,11-dihydro-5H-dibenzo[1,2-a:1',4'-e][7]annulen-11-yl)imidazole
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass329.22 g·mol−1
3D model (JSmol)
  • C1CC2=CC(=CC(=C2C(C3=CC=CC=C31)N4C=CN=C4)Cl)Cl
  • InChI=1S/C18H14Cl2N2/c19-14-9-13-6-5-12-3-1-2-4-15(12)18(17(13)16(20)10-14)22-8-7-21-11-22/h1-4,7-11,18H,5-6H2

Eberconazole is an antifungal drug. As a 1% topical cream, it is an effective treatment for dermatophytosis, candidiasis, and pityriasis.[1][2][3]

It was approved for use in Spain in 2015 and is sold under the trade name Ebernet.[4] It is also approved for use in Panama, Guatemala, Costa Rica, Honduras, and the Dominican Republic.[1]


  1. ^ a b "Ebernet". NewBridge Pharmaceuticals. Archived from the original on 2016-04-24. Retrieved 2017-01-15.
  2. ^ del Palacio A, Ortiz FJ, Pérez A, Pazos C, Garau M, Font E (2001). "A double-blind randomized comparative trial: eberconazole 1% cream versus clotrimazole 1% cream twice daily in Candida and dermatophyte skin infections". Mycoses. 44 (5): 173–80. doi:10.1046/j.1439-0507.2001.00632.x. PMID 11486455.
  3. ^ Repiso Montero T, López S, Rodríguez C, del Rio R, Badell A, Gratacós MR (May 2006). "Eberconazole 1% cream is an effective and safe alternative for dermatophytosis treatment: multicenter, randomized, double-blind, comparative trial with miconazole 2% cream". International Journal of Dermatology. 45 (5): 600–4. doi:10.1111/j.1365-4632.2006.02841.x. PMID 16700802.
  4. ^ "Eberconazole". Drugs.com.